Search Results for: STK11

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
MYC MYC proto-oncogene, bHLH transcription factor
  • Transcription of E2F targets under negative control by DREAM complex
  • NOTCH1 Intracellular Domain Regulates Transcription
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Binding of TCF/LEF:CTNNB1 to target gene promoters
  • MAPK6/MAPK4 signaling
  • Ub-specific processing proteases
  • Interleukin-4 and Interleukin-13 signaling
  • Cyclin E associated events during G1/S transition
  • Cyclin A:Cdk2-associated events at S phase entry
  • TFAP2 (AP-2) family regulates transcription of cell cycle factors
  • RUNX3 regulates WNT signaling
  • Estrogen-dependent gene expression
  • Transcriptional regulation of granulopoiesis
  • Acetylsalicylic acid
  • Nadroparin
  • Choriocarcinoma
  • Penile cancer
  • Burkitt lymphoma
  • Oral cancer
  • Acute lymphoblastic leukemia (ALL) (precursor T lymphoblastic leukemia)
  • Multiple myeloma
  • Small cell lung cancer
  • Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)
  • Osteosarcoma
  • Kaposi's sarcoma
  • Laryngeal cancer
  • Breast cancer
  • Ovarian cancer
NANS N-acetylneuraminate synthase
  • Sialic acid metabolism
NAT2 N-acetyltransferase 2
  • Acetylation
NF2 neurofibromin 2
  • Regulation of actin dynamics for phagocytic cup formation
  • RHO GTPases activate PAKs
  • Malignant pleural mesothelioma
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
PARD3 par-3 family cell polarity regulator
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • Tight junction interactions
PDGFRA platelet derived growth factor receptor alpha
  • PIP3 activates AKT signaling
  • Downstream signal transduction
  • Signaling by PDGF
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Imatinib-resistant PDGFR mutants
  • Sunitinib-resistant PDGFR mutants
  • Regorafenib-resistant PDGFR mutants
  • Sorafenib-resistant PDGFR mutants
  • PDGFR mutants bind TKIs
  • Becaplermin
  • Imatinib
  • Sunitinib
  • XL820
  • Olaratumab
  • Pazopanib
  • Midostaurin
  • Regorafenib
  • Ponatinib
  • Lenvatinib
  • Nintedanib
  • Foreskin keratinocyte (neonatal)
  • Fostamatinib
  • Erdafitinib
  • Amuvatinib
  • Ripretinib
  • Glioma
PDXP pyridoxal phosphatase
  • Pyridoxal phosphate
PHF23 PHD finger protein 23
PIK3CA phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha
  • PI3K Cascade
  • IRS-mediated signalling
  • GPVI-mediated activation cascade
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PI3K events in ERBB4 signaling
  • PIP3 activates AKT signaling
  • Signaling by SCF-KIT
  • Synthesis of PIPs at the plasma membrane
  • GAB1 signalosome
  • Signaling by cytosolic FGFR1 fusion mutants
  • Downstream signal transduction
  • PI3K events in ERBB2 signaling
  • PI3K/AKT activation
  • Downstream TCR signaling
  • Role of phospholipids in phagocytosis
  • Tie2 Signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • DAP12 signaling
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Nephrin family interactions
  • Costimulation by the CD28 family
  • CD28 dependent PI3K/Akt signaling
  • G alpha (q) signalling events
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • Constitutive Signaling by EGFRvIII
  • PI-3K cascade:FGFR1
  • PI-3K cascade:FGFR2
  • PI-3K cascade:FGFR3
  • PI-3K cascade:FGFR4
  • Signaling by FGFR2 in disease
  • Signaling by FGFR4 in disease
  • Signaling by FGFR1 in disease
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • MET activates PI3K/AKT signaling
  • Signaling by FGFR3 fusions in cancer
  • Signaling by FGFR3 point mutants in cancer
  • RET signaling
  • Extra-nuclear estrogen signaling
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Activated NTRK2 signals through PI3K
  • Interleukin receptor SHC signaling
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • Activated NTRK3 signals through PI3K
  • FLT3 Signaling
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 ITD and TKD mutants
  • ATP
  • Caffeine
  • XL765
  • Wortmannin
  • Pilaralisib
  • Alpelisib
  • Copanlisib
  • Ovarian cancer
PLD3 phospholipase D family member 3
  • Synthesis of PG
  • Role of phospholipids in phagocytosis
PPP2CB protein phosphatase 2 catalytic subunit beta
  • Inhibition of replication initiation of damaged DNA by RB1/E2F1
  • Spry regulation of FGF signaling
  • Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
  • Integration of energy metabolism
  • PP2A-mediated dephosphorylation of key metabolic factors
  • DARPP-32 events
  • Degradation of beta-catenin by the destruction complex
  • Beta-catenin phosphorylation cascade
  • ERK/MAPK targets
  • ERKs are inactivated
  • MASTL Facilitates Mitotic Progression
  • Separation of Sister Chromatids
  • Resolution of Sister Chromatid Cohesion
  • CTLA4 inhibitory signaling
  • Platelet sensitization by LDL
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Signaling by GSK3beta mutants
  • S33 mutants of beta-catenin aren't phosphorylated
  • S37 mutants of beta-catenin aren't phosphorylated
  • S45 mutants of beta-catenin aren't phosphorylated
  • T41 mutants of beta-catenin aren't phosphorylated
  • APC truncation mutants have impaired AXIN binding
  • AXIN missense mutants destabilize the destruction complex
  • Truncations of AMER1 destabilize the destruction complex
  • RHO GTPases Activate Formins
  • RAF activation
  • Negative regulation of MAPK pathway
  • Regulation of TP53 Degradation
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Mitotic Prometaphase
  • Cyclin D associated events in G1
  • Cyclin A/B1/B2 associated events during G2/M transition
  • Regulation of glycolysis by fructose 2,6-bisphosphate metabolism
  • EML4 and NUDC in mitotic spindle formation
  • Vitamin E
PRKAA1 protein kinase AMP-activated catalytic subunit alpha 1
  • Macroautophagy
  • Energy dependent regulation of mTOR by LKB1-AMPK
  • TP53 Regulates Metabolic Genes
  • Regulation of TP53 Activity through Phosphorylation
  • Activation of AMPK downstream of NMDARs
  • Adenosine phosphate
  • Adenosine phosphate
  • ATP
  • Phenformin
  • Acetylsalicylic acid
  • Fostamatinib
  • Fostamatinib
PRKAA2 protein kinase AMP-activated catalytic subunit alpha 2
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • Macroautophagy
  • AMPK inhibits chREBP transcriptional activation activity
  • AMPK inhibits chREBP transcriptional activation activity
  • Carnitine metabolism
  • Activation of PPARGC1A (PGC-1alpha) by phosphorylation
  • Energy dependent regulation of mTOR by LKB1-AMPK
  • TP53 Regulates Metabolic Genes
  • Regulation of TP53 Activity through Phosphorylation
  • Lipophagy
  • Activation of AMPK downstream of NMDARs
  • Adenosine phosphate
  • Acetylsalicylic acid
  • Fostamatinib
PRKACA protein kinase cAMP-activated catalytic subunit alpha
  • PKA-mediated phosphorylation of CREB
  • PKA-mediated phosphorylation of key metabolic factors
  • Triglyceride catabolism
  • PKA activation
  • PKA activation in glucagon signalling
  • DARPP-32 events
  • Regulation of PLK1 Activity at G2/M Transition
  • Loss of Nlp from mitotic centrosomes
  • Recruitment of mitotic centrosome proteins and complexes
  • Loss of proteins required for interphase microtubule organization from the centrosome
  • Recruitment of NuMA to mitotic centrosomes
  • Glucagon-like Peptide-1 (GLP1) regulates insulin secretion
  • Glucagon-like Peptide-1 (GLP1) regulates insulin secretion
  • Rap1 signalling
  • Regulation of insulin secretion
  • Vasopressin regulates renal water homeostasis via Aquaporins
  • VEGFA-VEGFR2 Pathway
  • CREB1 phosphorylation through the activation of Adenylate Cyclase
  • CREB1 phosphorylation through the activation of Adenylate Cyclase
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • Ion homeostasis
  • Degradation of GLI1 by the proteasome
  • Degradation of GLI2 by the proteasome
  • GLI3 is processed to GLI3R by the proteasome
  • Hedgehog 'off' state
  • Anchoring of the basal body to the plasma membrane
  • CD209 (DC-SIGN) signaling
  • MAPK6/MAPK4 signaling
  • RET signaling
  • AURKA Activation by TPX2
  • HDL assembly
  • ROBO receptors bind AKAP5
  • Loss of phosphorylation of MECP2 at T308
  • Regulation of MECP2 expression and activity
  • Regulation of glycolysis by fructose 2,6-bisphosphate metabolism
  • ADORA2B mediated anti-inflammatory cytokines production
  • ADORA2B mediated anti-inflammatory cytokines production
  • FCGR3A-mediated IL10 synthesis
  • FCGR3A-mediated IL10 synthesis
  • Factors involved in megakaryocyte development and platelet production
  • Pentanal
  • Balanol Analog 2
  • 3-[(3-sec-butyl-4-hydroxybenzoyl)amino]azepan-4-yl 4-(2-hydroxy-5-methoxybenzoyl)benzoate
  • Phosphonothreonine
  • Balanol Analog 1
  • 3,5-Diiodotyrosine
  • Balanol
  • Dexfosfoserine
  • S,S-(2-Hydroxyethyl)Thiocysteine
  • Hydroxyfasudil
  • (2S)-1-(3H-Indol-3-yl)-3-{[5-(6-isoquinolinyl)-3-pyridinyl]oxy}-2-propanamine
  • (2S)-1-{[5-(1H-Indazol-5-yl)-3-pyridinyl]oxy}-3-(7aH-indol-3-yl)-2-propanamine
  • (1S)-2-(1H-INDOL-3-YL)-1-[({5-[(E)-2-PYRIDIN-4-YLVINYL]PYRIDIN-3-YL}OXY)METHYL]ETHYLAMINE
  • (2S)-1-(6H-INDOL-3-YL)-3-{[5-(7H-PYRAZOLO[3,4-C]PYRIDIN-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE
  • (1S)-1-(1H-INDOL-3-YLMETHYL)-2-(2-PYRIDIN-4-YL-[1,7]NAPHTYRIDIN-5-YLOXY)-EHYLAMINE
  • N-[(1S)-2-AMINO-1-(2,4-DICHLOROBENZYL)ETHYL]-5-[2-(METHYLAMINO)PYRIMIDIN-4-YL]THIOPHENE-2-CARBOXAMIDE
  • 3-(1H-indol-3-yl)-4-{1-[2-(1-methylpyrrolidin-2-yl)ethyl]-1H-indol-3-yl}-1H-pyrrole-2,5-dione
  • (4R,2S)-5'-(4-(4-CHLOROBENZYLOXY)PYRROLIDIN-2-YLMETHANESULFONYL)ISOQUINOLINE
  • N-METHYL-1-[4-(9H-PURIN-6-YL)PHENYL]METHANAMINE
  • (S)-1-PHENYL-1-[4-(9H-PURIN-6-YL)PHENYL]METHANAMINE
  • 6-{4-[4-(4-CHLOROPHENYL)PIPERIDIN-4-YL]PHENYL}-9H-PURINE
  • (2R)-2-(4-chlorophenyl)-2-[4-(1H-pyrazol-4-yl)phenyl]ethanamine
  • (2S)-2-(4-chlorophenyl)-2-[4-(1H-pyrazol-4-yl)phenyl]ethanamine
  • 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE
  • (2R)-2-(4-CHLOROPHENYL)-2-PHENYLETHANAMINE
  • (S)-2-METHYL-1-[(4-METHYL-5-ISOQUINOLINE)SULFONYL]-HOMOPIPERAZINE
  • ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE
  • H-89
  • 5-(2-methylpiperazine-1-sulfonyl)isoquinoline
  • N-[2-(METHYLAMINO)ETHYL]-5-ISOQUINOLINESULFONAMIDE
  • 2-[4-(3-METHYL-1H-PYRAZOL-4-YL)PHENYL]ETHANAMINE
  • (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE
  • 3-pyridin-4-yl-1H-indazole
  • 5-benzyl-1,3-thiazol-2-amine
  • 1-[4-(4-chlorophenyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine
  • 1-[4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine
  • 4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-aminium
  • Fasudil
  • Myristic acid
  • A-674563
  • 3-PYRIDIN-4-YL-2,4-DIHYDRO-INDENO[1,2-.C.] PYRAZOLE
  • Y-27632
  • Ellagic acid
  • Fostamatinib
PRSS50 serine protease 50
PTEN phosphatase and tensin homolog
  • Synthesis of PIPs at the plasma membrane
  • Synthesis of IP3 and IP4 in the cytosol
  • Negative regulation of the PI3K/AKT network
  • Downstream TCR signaling
  • TP53 Regulates Metabolic Genes
  • PTEN Loss of Function in Cancer
  • Ub-specific processing proteases
  • Ovarian tumor domain proteases
  • Regulation of PTEN mRNA translation
  • Regulation of PTEN localization
  • Regulation of PTEN stability and activity
  • Transcriptional Regulation by MECP2
  • Phosphatidylethanolamine
  • Vulvar cancer
  • Prostate cancer
  • Endometrial Cancer
  • Glioma
  • Small cell lung cancer
  • Breast cancer
  • Hepatocellular carcinoma
  • Malignant melanoma
RASA1 RAS p21 protein activator 1
  • Downstream signal transduction
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • VEGFR2 mediated cell proliferation
  • Regulation of RAS by GAPs
  • PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
  • RASA1-related disorders, including: Parkes-Weber slndrome; Capillary malformation-arteriovenous malformation (CM-AVM); Arteriovenous fistula (AVF)
RASSF1 Ras association domain family member 1
  • Non-small cell lung cancer
  • Bladder cancer
  • Nasopharyngeal cancer
RHOBTB2 Rho related BTB domain containing 2
  • RHOBTB2 GTPase cycle
RPS6KA3 ribosomal protein S6 kinase A3
  • ERK/MAPK targets
  • CREB phosphorylation
  • Senescence-Associated Secretory Phenotype (SASP)
  • Senescence-Associated Secretory Phenotype (SASP)
  • Recycling pathway of L1
  • CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling
  • RSK activation
  • RSK activation
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Acetylsalicylic acid
  • Fostamatinib
  • Non-syndromic X-linked mental retardation
  • Coffin-Lowry syndrome (CLS)

Page 5 out of 7 pages